C.E. McCarron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
C.E. McCarron has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
G.S. Zaric
Ivey Business School at Western University, London, ON
1 shared publicationJ.Q. Cao
London Regional Cancer Program, London, ON
1 shared publicationS. Ernst
London Regional Cancer Program, London, ON
1 shared publication
Latest Publications
- Open Access
- 1 October 2015
- Published by MDPI AG in Current Oncology
- Vol. 22 (5) , 326-332
Population-Based Estimates of Survival and Cost for Metastatic Melanoma
Background Fewer than half of all patients with metastatic melanoma survive more than 1 year. Standard treatments have had little success, but recent therapeutic advances offer the potential for an improved prognosis. In the present study, we used population-based administrative data to establish real-world baseline estimates of survival outcomes and costs against which new treatments can be compared. Methods Data from administrative databases and patient registries were used to find a cohort of patients with metastatic melanoma in Ontario. To identify individuals most likely to receive new treatments, we focused on patients eligible for second-line treatment. The identified cohort had two characteristics:no surgical resection beyond primary skin excision, and receipt of first-line systemic therapy. Results Patient characteristics, Kaplan–Meier survival curves, and mean costs are reported. Of the 33,585 patients diagnosed with melanoma in Ontario from 1 January 1991 to 31 December 2010, 278 met the study inclusion criteria. Average age was 63 years, and 62% of the patients were men. Overall survival was estimated to be 19%, 12%, and 6% at 12, 24, and 60 months respectively. Mean survival time was 11.5 months, and mean cost was $30,685. Conclusions Our baseline estimates indicate that survival outcomes are poor and costs are high for patients receiving standard treatment. Understanding the relative improvement accruing from any new treatment requires a comparison with the existing standard of care.
- 1 October 2015
- Published by MDPI AG in Current Oncology
- Vol. 22 (5) , 326-332
Open AccessPopulation-Based Estimates of Survival and Cost for Metastatic Melanoma
Background Fewer than half of all patients with metastatic melanoma survive more than 1 year. Standard treatments have had little success, but recent therapeutic advances offer the potential for an improved prognosis. In the present study, we used population-based administrative data to establish real-world baseline estimates of survival outcomes and costs against which new treatments can be compared. Methods Data from administrative databases and patient registries were used to find a cohort of patients with metastatic melanoma in Ontario. To identify individuals most likely to receive new treatments, we focused on patients eligible for second-line treatment. The identified cohort had two characteristics:no surgical resection beyond primary skin excision, and receipt of first-line systemic therapy. Results Patient characteristics, Kaplan–Meier survival curves, and mean costs are reported. Of the 33,585 patients diagnosed with melanoma in Ontario from 1 January 1991 to 31 December 2010, 278 met the study inclusion criteria. Average age was 63 years, and 62% of the patients were men. Overall survival was estimated to be 19%, 12%, and 6% at 12, 24, and 60 months respectively. Mean survival time was 11.5 months, and mean cost was $30,685. Conclusions Our baseline estimates indicate that survival outcomes are poor and costs are high for patients receiving standard treatment. Understanding the relative improvement accruing from any new treatment requires a comparison with the existing standard of care.